Scientists use new imaging to peek inside brown fat in diabetes
NCT ID NCT05092945
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how brown adipose tissue (brown fat) works in people with type 2 diabetes. Researchers used special PET scans with a fat-based tracer to measure brown fat activity more accurately than before. The study included 6 participants and aimed to better understand how brown fat burns energy, which could help develop new treatments for diabetes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
6 people
The number who actually took part.
- Started
-
May 2021
- Finished
-
Aug 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 10 men and 10 women with T2D. * 10 non-diabetic men and 10 non-diabetic women (matched for sex, BMI and age to the T2D participants). Exclusion Criteria: * Change in weight of more than 2 kg over the past 3 months or recent changes in lifestyle; * Treatment with a fibrate, thiazolidinedione, insulin, beta-blocker, GLP-1 agonist, or other drug known to affect lipid or carbohydrate metabolism, except statins, metformin, sulfonylurea, DPP-IV inhibitor and other antihypertensive agents that can be temporarily stopped safely prior to the studies, as per our approved protocols; * Presence of overt cardiovascular, liver, renal or other medical conditions; * Smoking or consumption of more than 2 alcoholic beverages per day; * Any other contraindication to temporarily suspending current medications for lipids or hypertension; * Any contraindication to MRI scanning. * Having participated to a research study with exposure to radiation in the last two years before the start of the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Type 2 diabetes are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre de recherche du CHUS
Sherbrooke, Quebec, J1H 5N4, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can mindfulness and yoga rewire diabetes habits?
- Can a vegan diet delivered online help people with type 2 diabetes?
- Tiny horses, big lessons: can ponies help kids tame diabetes?
- Gut microbes in pregnancy and infancy: a window into lifelong health?
- A blood test at 50 could flag your risk of five diseases. can an app stop them?
- Chatbot coach takes aim at diabetes risk after pregnancy